003017 Zhejiang Dayang Biotech Group
- 18.86
- -0.34-1.77%
Zhejiang Dayang Biotech Group News
Ocean Bio: Report for the third quarter of 2024
zhejiang dayang biotech group (003017.SZ) released its performance for the first three quarters, with a net income of 51.27 million yuan, a year-on-year increase of 27.60%.
Zhitoong Finance APP News, zhejiang dayang biotech group (003017.SZ) released the third quarter report of 2024, during the reporting period, the company achieved revenue...
zhejiang dayang biotech group (003017.SZ): plan to invest 0.302 billion yuan to build an annual production of 800 tons of ammeline hydrochloride relocation and expansion technical transformation project.
Zhejiang Dayang Biotech Group (003017.SZ) announced that on October 17, 2024, the company held the 20th meeting of the fifth board of directors to review and approve the proposal on investing in the construction of an annual output of 800 tons of amphotericin B hydrochloride relocation and expansion project. The board agreed to invest 0.3019 billion RMB of self-raised funds in the construction of the project. This is to further expand the operation scale of the company's flagship products, enhance product market competitiveness, and also respond to Jiande City's policy of replacing polluting industries with emerging ones and industrial transformation, by incorporating existing hazardous chemicals.
zhejiang dayang biotech group (003017.SZ) plans to invest 0.302 billion yuan to build a project for relocating and expanding the annual production of 800 tons of amine propanol chloride.
Zhītōng Cáijīn APP News, zhejiang dayang biotech group (003017.SZ) announced that the company plans to use self-raised funds of 0.302 billion yuan RMB (currency below...
Express News | Zhejiang Dayang Biotech Group: investing 0.302 billion yuan to build an annual output of 800 tons of amine propranolol hydrochloride relocation and expansion technological transformation project.
Zhejiang Dayang Biotech Group (003017.SZ): The employee stock ownership plan for 2024 has been completed without any trade transfers.
On September 10th, Gelunhui announced that on September 10th, 2024, the company received the "Confirmation of Securities Transfer Registration" issued by China Securities Depository and Clearing Corporation Limited, Shenzhen Branch. The 1,947,030 shares of the company's stocks held by the "Zhejiang Dayang Biotech Group Co., Ltd. Repurchase Special Securities Account" were transferred on September 9th, 2024 to the "Zhejiang Dayang Biotech Group Co., Ltd. - 2024 Employee Stock Ownership Plan" Account. The transferred shares account for 2.32% of the total share capital of the company. This employee stock ownership plan is completed through non-trading.
Ocean Life: 2024 Semi-Annual Report Summary
Ocean Life: 2024 Semi-Annual Report
Zhejiang Dayang Biotech Group (003017.SZ) released its performance for the first half of the year, with a net income of 31.4363 million yuan, an increase of 31.77%.
Zhejiang Dayang Biotech Group (003017.SZ) released its semi-annual report for 2024, during which the company achieved revenue...
Zhejiang Dayang Biotech Group (003017.SZ): has repurchased 3.23% of the shares.
Zhejiang Dayang Biotech Group (003017.SZ) announced on August 1st that as of July 31st, 2024, the company had repurchased a total of 2,716,000 shares through a repurchase special securities account by means of centralized bidding trading, accounting for 3.2333% of the total share capital of the company. The highest fill price was 17.50 yuan/share, and the lowest fill price was 12.61 yuan/share, with a total transaction amount of 41.9555 million yuan (excluding transaction fees).
Zhejiang Dayang Biotech Group (003017.SZ) plans to launch an employee stock ownership plan in 2024, with a stock scale not exceeding 1.947 million shares.
Zhejiang Dayang Biotech Group (003017.SZ) has released the draft of the employee stock ownership plan for 2024, in which employees can participate...
Zhejiang Dayang Biotech Group (003017.SZ) has repurchased 3.14% of its shares.
Zhejiang Dayang Biotech Group (003017.SZ) announced that as of July 11, 2024, the company had repurchased a total of 2.6358 million shares through its repurchase special securities account in a centralized bidding transaction, accounting for 3.1379% of the company's total share capital. The highest fill price was 17.50 yuan/share and the lowest fill price was 12.61 yuan/share. The total trading amount was 40.74579 million yuan (excluding transaction fees).
Zhejiang Dayang Biotech Group (003017.SZ): There is currently no business related to synthetic biology.
On July 4th, Gelonhui reported that an investor asked Dayang Biotech Group (003017.SZ) on the investor interaction platform, "Does the company have any synthetic biology-related businesses?" The company responded that the company does not currently have any synthetic biology-related businesses.
Zhejiang Dayang Biotech Group (003017.SZ) announced the distribution of 10 shares and a dividend of 4.5 yuan for the fiscal year 2023, with a registration date on July 10.
Zhejiang Dayang Biotech Group (003017.SZ) announced that the company's annual equity distribution plan for 2023 is: Based on the company's existing total share capital of 84,000,000 shares, excluding 2,505,000 repurchased shares, the base number is 81,495,000 shares. A cash dividend of 4.500000 yuan (tax included) will be distributed to all shareholders for every 10 shares held. The equity distribution registration date for this time is July 10, 2024; the ex-dividend date is July 11, 2024.
Zhejiang Dayang Biotech Group (003017.SZ) has repurchased 2.982% of its shares.
Zhejiang Dayang Biotech Group (003017.SZ) announced that as of June 28, 2024, the company has repurchased a total of 2,505,000 shares of company stocks, accounting for 2.9821% of the total shares, through a repurchase special securities account using centralized bidding transaction method. The highest fill price is 17.50 yuan/share, the lowest fill price is 12.61 yuan/share, and the total trading amount is 38.71235 million yuan (excluding trading fees).
Zhejiang Dayang Biotech Group (003017.SZ): Employee stock ownership plan share sales completed in 2022.
On June 7, Gelunhui reported that Zhejiang Dayang Biotech Group (stock code: 003017.SZ) announced that as of the date of this announcement, the remaining 2,422,168 shares of the company's stocks held by employees under the 2022 employee shareholding plan (accounting for 2.8835% of the total share capital of the company) have been sold through centralized bidding trading.
Ocean Biotech (003017.SZ): 2.68% of shares have been repurchased cumulatively
Gelonghui, May 6, 丨 Ocean Biotech (003017.SZ) announced that as of April 30, 2024, the company had repurchased 2,253,500 shares of the company's shares through a dedicated securities account, accounting for 2.6827% of the company's total share capital. The highest transaction price was 17.50 yuan/share, the lowest transaction price was 12.61 yuan/share, and the cumulative transaction amount was 34,615,711.07 yuan (not including transaction fees).
Ocean Biotech (003017.SZ): Net profit of 16.918 million yuan in the first quarter decreased by 12.78% year-on-year
On April 25, GLONGHUI (003017.SZ) released its first quarter report. Operating revenue was 190 million yuan, down 22.46% year on year, net profit of 16.918 million yuan, down 12.78% year on year. After deducting non-net profit of 15.756 million yuan, a year-on-year decrease of 6.53%, with basic earnings per share of 0.21 yuan.
Ocean Biotech (003017.SZ): Has its own power plant to produce electricity and steam for daily production of a small amount of external supply
Gelonghui, April 10 | Ocean Biotech (003017.SZ) said on the investor interactive platform that the company has its own power plant to produce electricity and steam for daily production, with a small amount of external supply.
Ocean Biotech (003017.SZ): There is currently no natural gas-related business
Gelonghui, April 10 | Ocean Biotech (003017.SZ) said on the investor interactive platform that the company currently has no natural gas-related business.
Analysis
Price Target
No Data
No Data